Close Menu

Editas

CRISPR for Blindness

According to the Associated Press, a patient has undergone gene editing to treat an inherited form of blindness.

The NAM, NAS, and Royal Society have formed a commission to develop a framework on the proper use of genome editing, and convened its first meeting in Washington, DC, this week.

The first trial using CRISPR within the human body is to begin this fall to treat a form of blindness.

 

Editas exclusively licensed the new enzyme, Alt-R Cas12a (Cpf1) Ultra, a mutant of Acidaminococcus sp. BV3L6 Cas12a (Cpf1), from IDT for therapeutic applications.

Early-access users have used IDT's rhAmpSeq technology to create genetic marker maps for plants and to validate off target events in gene editing.

 

The court upheld a judgement of no interference-in-fact from the Patent Trial and Appeal Board, leaving the Broad in control of key CRISPR IP.

In exchange, Editas has the exclusive right to be the first to negotiate for licenses to genome-editing inventions that arise from the sponsored research.

The company — which was cofounded by David Liu, Feng Zhang, and Keith Joung — has licensed base editing technology from Harvard and the Broad Institute.

Ready to Go, But?

Technology Review writes that though CRISPR trials in people are beginning, studies in monkeys haven't provided much data.

On the Verge

The Financial Times reports that CRISPR-based biotechs are about to start human studies of gene-editing treatments.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.